Cellular Therapy
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
From the Journals
Gene therapy restored immunity in newly diagnosed SCID-X1
In the phase 1/2 study, seven infants had normal immune cells 3-4 months after treatment, while the eighth infant responded after a gene therapy...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
From the Journals
Infant survival rate after HCT remains flat
Survival rates remained largely unchanged from 2000-2014 for infants who underwent allogeneic hematopoietic cell...
Conference Coverage
MRD status at transplant predicts outcomes in ALL patients
HOUSTON – Acute lymphoblastic leukemia patients with measurable residual disease (MRD) negativity prior to...
Conference Coverage
Secondary AML in first remission predicts outcomes
HOUSTON – Secondary AML predicts outcomes after SCT in first complete remission, whereas factors such as age, cytogenetics, and performance status...
Conference Coverage
Haplo-HSCT bests chemotherapy for MRD-positive adult ALL
HOUSTON – Haplo-HSCT outperforms chemotherapy for the treatment of adults with ALL in first complete response, particularly MRD-positive patients...
Conference Coverage
Therapeutic dosing of busulfan helps reduce relapse in ASCT
HOUSTON - Pharmacokinetic-directed therapeutic dose monitoring of busulfan used in combination with cyclophosphamide and etoposide appears to...
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
From the Journals
Weak evidence surrounds use of mesenchymal stem cells
A Cochrane review found weak evidence to support limited use of mesenchymal stem cells in hematopoietic transplant.